Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Claris Biotherapeutics | Jersey City | Series B | $118.0M | 2026-07-28 |
| Windward Bio | Basel | Series B | $165.0M | 2026-05-04 |
| ADCendo | Copenhagen | Series C | $75.0M | 2026-04-14 |
| Bluejay Therapeutics | San Mateo | Series C | $182.0M | 2024-05-09 |
| Reunion Neuroscience | Toronto | Series A | $133.0M | 2025-09-16 |
| Asgard Therapeutics | Lund | Series A | $32.6M | 2024-03-14 |
| Doctor Anywhere | Singapore | Series C | $40.8M | 2023-12-06 |
| Terremoto Biosciences | San Francisco | Series C | $108.0M | 2026-04-15 |
8 rows of the CSV in 5 of its 18 columns.
- The 29 Novo Holdings portfolio companies have raised $2.7B in total.
- 5 of them closed their most recent round in the last 12 months, $470.7M combined.
- The largest of those rounds is Windward Bio's $165.0M Series B, dated May 2026.
- The most recent is Claris Biotherapeutics' $118.0M Series B on 28 July 2026.
- OrbiMed is an investor in 4 of them, more than any other fund.
- Health care is the most common sector, with 23 companies (79%).
- 24% were founded in 2020 or later; the median founding year is 2017.
- The most common team size is 11 to 50 employees (52% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
18 of 29| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Claris Biotherapeutics | Claris Biotherapeutics develops biologic therapies for corneal diseases and ocular surface disorders. | Biotech | Jersey City, United States | Series B | $118.0M | 2026-07-28 | $225.1M | RA Capital Management, Novo Holdings, Janus Henderson Investors +1 | 1 to 10 | 2018 |
| Windward Bio | Windward Bio develops monoclonal antibodies for advanced immunological diseases. | Biotech | Basel, Switzerland | Series B | $165.0M | 2026-05-04 | $365.0M | Qiming Venture Partners, OrbiMed, Novo Holdings +2 | 11 to 50 | 2024 |
| Terremoto Biosciences | Terremoto Biosciences develops medicines using lysine-based covalent chemistry. | Biotech | San Francisco, United States | Series C | $108.0M | 2026-04-15 | $358.0M | OrbiMed, Novo Holdings, Third Rock Ventures +2 | 51 to 100 | 2021 |
| ADCendo | ADCendo develops antibody-drug conjugates to target cancers with high unmet medical needs. | Biotech | Copenhagen, Denmark | Series C | $75.0M | 2026-04-14 | $324.6M | RA Capital Management, Novo Holdings, Gilde Healthcare +2 | 51 to 100 | 2017 |
| Reunion Neuroscience | Reunion Neuroscience develops therapeutic treatments for underserved mental health conditions. | Biotech | Toronto, Canada | Series A | $133.0M | 2025-09-16 | $133.0M | Novo Holdings, Mitsui Global Investment, MPM Capital +2 | 1 to 10 | 2019 |
| Commit Biologics | Commit Biologics develops a novel immunotherapy platform for treating cancer. | Biotech | Aarhus, Denmark | Seed | $5.7M | 2025-01-28 | $23.7M | Novo Holdings, Innovation Fund Denmark, Bioqube Ventures | 11 to 50 | 2021 |
| Asceneuron | Asceneuron develops therapeutics for orphan tauopathies and Alzheimer's disease. | Biotech | Lausanne, Switzerland | Series C | $100.0M | 2024-07-16 | OrbiMed, Novo Holdings, EQT Life Sciences +1 | 1 to 10 | 2012 | |
| Bluejay Therapeutics | Bluejay Therapeutics is a private biopharmaceutical company developing cures for infectious diseases. | Biotech | San Mateo, United States | Series C | $182.0M | 2024-05-09 | $242.2M | RA Capital Management, Wellington Management, Novo Holdings +2 | 11 to 50 | 2019 |
| Asgard Therapeutics | Asgard Therapeutics is a biotechnology company developing new therapies. | Biotech | Lund, Sweden | Series A | $32.6M | 2024-03-14 | $39.6M | Novo Holdings, Industrifonden, Boehringer Ingelheim Venture Fund +2 | 11 to 50 | 2018 |
| Elo Life Systems | Elo Life Systems is a biotechnology company that studies how food supports human health and wellness. | Biotech | Durham, United States | Series A | $20.5M | 2024-01-24 | $56.5M | Novo Holdings, Alexandria Venture Investments, DCVC Bio +2 | 11 to 50 | 2006 |
| Hoba Therapeutics | Hoba Therapeutics develops a new therapeutic protein for treating neuropathic pain. | Biotech | Copenhagen, Denmark | Series A | $24.8M | 2023-12-11 | European Innovation Council, EIC Accelerator, Novo Holdings +2 | 1 to 10 | 2016 | |
| Doctor Anywhere | Doctor Anywhere is a telehealth company that connects patients with doctors remotely. | Health care | Singapore | Series C | $40.8M | 2023-12-06 | $176.4M | EDBI, Square Peg Capital, Novo Holdings +1 | 501 to 1,000 | 2016 |
| NMD Pharma | NMD Pharma discovers small molecule drugs for neuromuscular disorders. | Health care | Risskov, Denmark | Series B | $81.4M | 2023-11-15 | $171.5M | Novo Holdings, Inkef, Jeito Capital +2 | 11 to 50 | 1986 |
| Engimmune Therapeutics | Engimmune Therapeutics engineers T cell receptor therapies and develops products based on its platform. | Biotech | Basel, Switzerland | Seed | $15.8M | 2022-05-03 | Novo Holdings, Kinled Holding, Pureos Bioventures +1 | 11 to 50 | 2021 | |
| NBE-Therapeutics | NBE-Therapeutics develops oncology treatments for cancer patients. | Biotech | Basel, Switzerland | Series C | $22.0M | 2020-01-10 | $65.7M | Novo Holdings, Boehringer Ingelheim Venture Fund, PPF Group | 11 to 50 | 2012 |
| Therachon | Therachon is a global biotechnology company developing medicines for rare genetic diseases. | Biotech | Basel, Switzerland | Series B | $60.0M | 2018-08-09 | $100.0M | Bpifrance, New Enterprise Associates, OrbiMed +2 | 1 to 10 | 2014 |
| Inthera Bioscience | Inthera Bioscience develops inhibitors of intracellular protein interactions using a proprietary technology platform. | Biotech | Schlieren, Switzerland | Series A | $5.5M | 2018-06-26 | Microsoft Accelerator, Novo Holdings, M Ventures +2 | 11 to 50 | 2013 | |
| Synosia Therapeutics | Synosia Therapeutics develops and commercializes products for unmet needs in psychiatry and neurology. | Biotech | Basel, Switzerland | Series C | $30.0M | 2010-10-12 | $94.0M | Novo Holdings, Versant Ventures, 5AM Ventures +2 | 1 to 10 | 2006 |
Table 1. Novo Holdings portfolio companies: the 18 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 29.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Windward Bio | Windward Bio develops monoclonal antibodies for advanced immunological diseases. | Biotech | Basel, Switzerland | Series B | $165.0M | 2026-05-04 | $365.0M | Qiming Venture Partners, OrbiMed, Novo Holdings +2 | 11 to 50 | 2024 |
| 2 | Claris Biotherapeutics | Claris Biotherapeutics develops biologic therapies for corneal diseases and ocular surface disorders. | Biotech | Jersey City, United States | Series B | $118.0M | 2026-07-28 | $225.1M | RA Capital Management, Novo Holdings, Janus Henderson Investors +1 | 1 to 10 | 2018 |
| 3 | Terremoto Biosciences | Terremoto Biosciences develops medicines using lysine-based covalent chemistry. | Biotech | San Francisco, United States | Series C | $108.0M | 2026-04-15 | $358.0M | OrbiMed, Novo Holdings, Third Rock Ventures +2 | 51 to 100 | 2021 |
| 4 | ADCendo | ADCendo develops antibody-drug conjugates to target cancers with high unmet medical needs. | Biotech | Copenhagen, Denmark | Series C | $75.0M | 2026-04-14 | $324.6M | RA Capital Management, Novo Holdings, Gilde Healthcare +2 | 51 to 100 | 2017 |
Table 2. Novo Holdings portfolio companies: the 4 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | OrbiMed | Private equity firm | New York, United States | 4 | 14% | 2 | Windward Bio, Terremoto Biosciences |
| 2 | Export and Investment Fund | Government investment office | Hellerup, Denmark | 4 | 14% | 1 | Reduced |
| 3 | RA Capital Management | Startup incubator | Boston, United States | 3 | 10% | 2 | Claris Biotherapeutics, ADCendo |
| 4 | Inkef | Venture capital firm | Amsterdam, The Netherlands | 3 | 10% | ||
| 5 | HealthCap | Venture capital firm | Stockholm, Sweden | 2 | 7% | 1 | ADCendo |
| 6 | Boehringer Ingelheim Venture Fund | Corporate venture arm | Ingelheim Am Rhein, Germany | 2 | 7% | ||
| 7 | Abingworth | Private equity firm | London, United Kingdom | 2 | 7% | ||
| 8 | EQT Life Sciences | Private equity firm | Amsterdam, The Netherlands | 2 | 7% | ||
| 9 | M Ventures | Corporate venture arm | Amsterdam, The Netherlands | 2 | 7% | ||
| 10 | Versant Ventures | Venture capital firm | Menlo Park, United States | 2 | 7% | ||
| 11 | Janus Henderson Investors | Private equity firm | London, United Kingdom | 1 | 3% | 1 | Claris Biotherapeutics |
| 12 | Mass General Brigham Ventures | Corporate venture arm | Cambridge, United States | 1 | 3% | 1 | Claris Biotherapeutics |
| 13 | Blue Owl | Private equity firm | New York, United States | 1 | 3% | 1 | Windward Bio |
| 14 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 1 | 3% | 1 | Windward Bio |
| 15 | RTW Investments | Hedge fund | New York, United States | 1 | 3% | 1 | Windward Bio |
Table 3. Novo Holdings portfolio companies: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 23 | 79% | $2.3B |
| Biotech | 22 | 76% | $2.3B |
| Software | 2 | 7% | $122.1M |
| Artificial intelligence | 1 | 3% | $33.1M |
| Fintech | 1 | 3% |
Table 4. Novo Holdings portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Novo Holdings portfolio companies by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| Denmark | 10 | 34% |
| United States | 7 | 24% |
| Switzerland | 7 | 24% |
| Canada | 1 | 3% |
| Sweden | 1 | 3% |
| Singapore | 1 | 3% |
| United Kingdom | 1 | 3% |
| India | 1 | 3% |
Table 6. Novo Holdings portfolio companies by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| Copenhagen | 7 | 24% |
| Basel | 5 | 17% |
| San Mateo | 3 | 10% |
| Risskov | 2 | 7% |
| Jersey City | 1 | 3% |
| Toronto | 1 | 3% |
| Lund | 1 | 3% |
| Singapore | 1 | 3% |
| San Francisco | 1 | 3% |
| London | 1 | 3% |
| Aarhus | 1 | 3% |
| Lausanne | 1 | 3% |
Table 7. Novo Holdings portfolio companies by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| July 2026 | 1 | 20% | $118.0M |
| May 2026 | 1 | 20% | $165.0M |
| April 2026 | 2 | 40% | $183.0M |
| February 2026 | 1 | 20% | $4.7M |
Table 8. Novo Holdings portfolio companies: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 5 | 17% | $470.7M |
| 2025 | 4 | 14% | $161.9M |
| 2024 | 8 | 28% | $555.7M |
| 2023 | 5 | 17% | $209.5M |
| 2022 | 1 | 3% | $15.8M |
| 2021 | 1 | 3% |
Table 9. Novo Holdings portfolio companies by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 2 | 7% |
| 2020 to 2022 | 5 | 17% |
| 2015 to 2019 | 12 | 41% |
| 2010 to 2014 | 6 | 21% |
| Before 2010 | 4 | 14% |
Table 10. Novo Holdings portfolio companies by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 9 | 31% |
| 11 to 50 | 15 | 52% |
| 51 to 100 | 2 | 7% |
| 101 to 250 | 1 | 3% |
| 251 to 500 | 1 | 3% |
| 501 to 1,000 | 1 | 3% |
Table 11. Novo Holdings portfolio companies by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Novo Holdings is recorded as one of its investors. On 16 November 2026 that is 29 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 18 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 29 rows: 3 have no round amount, 0 no city and 2 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many Novo Holdings portfolio companies are on the list?
- 29, in the file dated 16 November 2026. 5 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 29 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.